Health experts are raising concerns as they detect a surge in a new COVID-19 variant, signalling a resurgence of respiratory infections nationwide. The emergence of the JN1 virus is attributed to mutations resulting from a high viral load, affecting individuals previously infected with other COVID-19 variants.
Doctor Shem Otoi, a specialist in studying COVID-19 waves, emphasized the increased contagiousness of the new variant compared to its predecessors. “From February onwards, we have observed a notable surge in this variant. Additionally, there is also the presence of the H1N1 influenza. The combination of these two respiratory threats raises significant concerns,” Dr. Otoi stated during a press briefing.
The JN1 Covid-19 symptoms
The symptoms associated with the JN1 variant include coughing, fatigue, shortness of breath, and chest congestion, with some cases also presenting with diarrhoea and abdominal pain. This variance in symptoms adds complexity to identifying and diagnosing the infection.
Despite ongoing efforts, there is currently no specific vaccine available for the JN1 variant. However, medical professionals are tirelessly working to develop treatments and vaccines that can provide broad protection against various COVID-19 strains. Dr. Otoi mentioned the XBB1.5 booster, which has shown promising results in providing cross-protection against multiple variants.
In terms of precautions, Dr. Otoi advised individuals experiencing symptoms similar to those of the new variant to undergo testing promptly. He also emphasized the importance of practising good hygiene and avoiding close contact with symptomatic individuals to curb the spread of the virus.
The World Health Organization (WHO) has reported a significant prevalence of the JN1 variant globally, with notable spikes in infections recorded in countries such as France, the United States, the United Kingdom, and Sweden. However, WHO has cautioned that data on the variant’s impact are still limited, urging vigilance and continued monitoring of its clinical outcomes.
“While the current prevalence of the JN1 variant is relatively low, caution is warranted due to insufficient data on disease severity associated with this variant,” a WHO statement highlighted. The organization stressed the need for ongoing research and data sharing to better understand and address the evolving challenges posed by COVID-19 variants.
As the situation unfolds, health authorities and medical professionals are urging the public to remain vigilant, follow preventive measures, and stay informed about developments related to the JN1 variant and other emerging threats in the fight against COVID-19.
